New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNY;BMY;MRK;JNJ;NVS;ABT;CELG;PFE;SHPG;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
January 12, 2015
09:30 EDTSHPGOn The Fly: Pre-market Movers
HIGHER: Foundation Medicine (FMI) up 138.9% following transaction with Roche (RHHBY)... Celator Pharmaceuticals (CPXX), up 19.1% after announcing promising Phase 2 data for CPX-351... Second Sight (EYES), up 16.7% after Health Canada approves Argus II retinal prosthesis system... Aegerion (AEGR), up 7.8% after reporting preliminary fourth quarter results and guidance... Express (EXPR), up 4.5% after reporting preliminary fourth quarter results. NOTABLE: NPS Pharmaceuticals (NPSP), up 8.5% following acquisition by Shire (SHPG)... Shire is down 1.1% in pre-market trading. LOWER: Arrowhead (ARWR), down 20.9% after FDA clears company to begin modified study of ARC-520 in a preliminary call of a partial clinical hold... Tiffany (TIF), down 10.4% after lowering fiscal 2014 net EPS guidance... SanDisk (SNDK), down 10.1% after lowering fourth quarter outlook... Ascena Retail (ASNA), down 5.8% after lowering fiscal 2015 adjusted EPS view... Sarepta Therapeutics (SRPT), down 5.9% after reporting long-term outcomes from Phase IIb Eteplirsen study... Loral Space & Communications (LORL), down 3.6% following a NY Post article that reported that talks to sell itself to the Ontario Teachers’ Pension Plan have ended... Southwestern Energy (SWN), down 4.2% after filing to sell 20.3M shares of stock and 26M depository shares.
09:22 EDTPFE23andMe announces collaboration with Pfizer
Google (GOOG)-backed 23andMe announced an agreement with Pfizer (PFE) that will provide Pfizer with access to 23andMe’s research platform, including services and Research Portal analysis of 23andMe’s genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe’s Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company’s unique research model while still protecting the privacy and security of 23andMe’s customers. As a part of the agreement, the companies will collaborate on certain genome-wide association studies, surveys, and clinical trial recruitment. One of these collaborations will be a longitudinal study to better understand the genetics of lupus. This study will entail enrollment and genotyping of 5,000 people into a new lupus research community, and include the integration of medical records, targeted bio-sampling along with genetic information for all participants. This announcement follows a collaboration between 23andMe and Pfizer to enroll 10,000 people with Inflammatory Bowel Disease in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Nearly 4,000 patients have been enrolled in the community since August 2014.
09:00 EDTBMYBristol-Myers price target raised to $70 from $62 at Argus
Subscribe for More Information
08:47 EDTSHPGShire acquisition favorable, says RBC Capital
Subscribe for More Information
08:37 EDTJNJ, BMY, SNY, MRK, PFE, NVS, SHPG, GSKShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:15 EDTBMYSeattle Genetics announces clinical trial collaboration with Bristol-Myers
Subscribe for More Information
08:14 EDTSHPGShire acquisition positive, says SunTrust
Subscribe for More Information
08:06 EDTBMYBristol-Myers shares expected to trade up around 10% at JPMorgan
JPMorgan expects shares of Bristol-Myers to trade up around 10% after the company announced that its Phase III trial of Opdivo in 2L squamous non-small cell lung cancer is stopping early due to efficacy. The firm views the news as a "clear positive" that sets up a potential 2015 filing and launch for the product in the 2L squamous market. It reiterates an Overweight rating on shares of the Bristol-Myers. The stock is up 7% to $64.25 in pre-market trading.
08:00 EDTSHPGShire deal for NPS Pharmaceuticals positive, says Susquehanna
Subscribe for More Information
07:56 EDTSHPGShire price target raised to $257 from $223 at William Blair
Subscribe for More Information
07:21 EDTMRK, JNJEBD Group to hold a conference
Subscribe for More Information
07:11 EDTSHPGNPS Pharmaceuticals volatility elevated into being acquired by Shire in a $5.2B
Subscribe for More Information
07:07 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:05 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
07:04 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:03 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
06:53 EDTMRKMerck to speed up plans for drug submission, WSJ says
Merck is speeding up its plans to submit new drugs for lung cancer and hepatitis C for regulatory approval, reports the Wall Street Journal. The company will file an application with the FDA around the mid-2015 to expand the use of Keytruda, the Journal adds. Reference Link
06:22 EDTGSK, MRKWHO approves 2 ebola vaccines to enter West Africa trials, Financial Times says
Subscribe for More Information
05:26 EDTBMYBristol-Myers up 5.6% after Opdivo Phase 3 study meets primary endpoint
Subscribe for More Information
05:06 EDTBMYBristol-Myers Opdivo Phase 3 study met primary endpoint
Bristol-Myers Squibb announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer, or NSCLC, was stopped early because an assessment conducted by the independent Data Monitoring Committee, or DMC, concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company will share these data – which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer – with health authorities. CheckMate -017 investigators are being informed of the decision to stop the comparative portion of the trial. Bristol-Myers Squibb is working to ensure that eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension as part of the company’s commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -017 data and work with investigators on the future presentation and publication of the results.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use